Murphy, who now lives in Alpine, Utah, started the organization in 2005 when performance-enhancing drugs were making news. It was in March of that year, for instance, when the former St. Louis Cardinals slugger Mark McGwire refused to answer questions before Congress about steroid use during his playing career.

“It really started with the steroids issue in baseball,” Murphy said in a telephone interview. “We were just sitting around, some of our friends, we just started talking, maybe we should just send another message out there because the perception of the kids is that everybody is taking this.”

Little League added the patch to World Series uniforms two years ago, giving the message more visibility. Little League does not test tournament players for drugs, but there are no regulations that stipulate whether local leagues can or cannot test.

In addition to greater substance use, young female steroid users were more likely to have had sexual intercourse before age 13; have been pregnant; drink and drive or have ridden with a drinking driver; carry a weapon; have been in a fight on school property; have feelings of sadness or hopelessness almost every day for at least two weeks; and have attempted suicide. Those reporting anabolic steroid use were less likely to participate in team athletics.

Overall, more than two-thirds of those surveyed reported trying to change their weight. Girls who used steroids were more likely try extreme weight-loss techniques, such as vomiting and laxative use.

Adolescent girls reporting anabolic steroid use had significantly more other health-harming behaviors, Elliot explained, “They were much more likely to use other unhealthy substances, including cigarettes, alcohol, marijuana and cocaine.”

Unlike the anabolic steroids athletes sometimes use illegally to bulk up muscle, corticosteroids are routinely used to treat inflammation in lupus patients. The drugs, however, can cause undesirable side effects including weight gain and acne when taken over long periods of time.

In a study published in a recent issue of Nature, researchers at UT Southwestern and other institutions show in blood cells that giving very high doses of intravenous corticosteroids early and frequently in the course of the disease is more effective at killing the cells that drive lupus than giving the standard limited intravenous steroids followed by high doses of oral corticosteroids over a period of months. The cells used came from lupus patients as well as from animal models of lupus.

“This finding is incredibly important, because humans are being treated with interferon for a variety of diseases, yet no one has tried treating asthma patients with interferon,” said Dr. J. David Farrar, assistant professor of immunology and molecular biology at UT Southwestern and senior author of the study. “The current therapies for asthma are inhalers and steroids, both of which offer only temporary relief.”

Asthma results in approximately 200,000 pediatric hospitalizations each year, more than for any other childhood disease. About 20 million people have been diagnosed with asthma in the U.S.

In the current study, the researchers showed in isolated human cells that interferon blocks the development of nascent Th2 cells and inhibits cells that already have become Th2 cells by interfering with a regulatory protein called GATA3, a transcription factor Th2 cells express to regulate their function.

Researchers found that 57 percent of patients who received combination therapy with infliximab and azathioprine achieved steroid-free remission after 26 weeks. This is compared to 44 percent of patients who achieved remission with infliximab monotherapy and 30 percent with azathioprine alone. Both the infliximab combination therapy and infliximab monotherapy groups were statistically superior to the azathioprine group. These results were durable through week 50 and overall results show comparable safety in the three groups.

Historically, patients with Crohn’s disease have been treated sequentially with steroids, then azathioprine, then monoclonal antibodies such as infliximab. The study definitively demonstrates that infliximab-based strategies are more effective than azathioprine, explains Dr. Sandborn.

“Results of this study will provide doctors and their patients with more information on how to use these drugs most appropriately to most effectively treat Crohn’s disease,” says Dr. Sandborn. “For the first time, we have longer term outcome data on the advantages of combination therapy that will help guide our treatment of patients with Crohn’s disease.”

The team led by Antonio Gómez-Muñoz, from the Department of Biochemistry and Molecular Biology at the Science and Technology Faculty of the University of the Basque Country (UPV/EHU), is investigating alternatives to current anti-inflammatory drugs, creating synthetic analogues of the C1P (ceramide-1-phosphate) molecule. This molecule was discovered in 1990 in a case of human leukaemia. After synthesising it in the laboratory, it was observed that it was an important mytogenic agent (provoking cell growth and blocking the natural death of the cells). Moreover, it causes cell inflammation, i.e. when the cells detect the presence of this molecule, they secrete molecules that generate inflammation - prostaglandin and cytokine cells, for example.

The side effects attributed to corticosteroids include decreased bone mineral density and reduced bone mass, and also in children, reduced growth rate. According to Dr. Green, strategies to alleviate these effects include minimizing oral doses and adding topical or inhaled steroids to provide the same anti-inflammatory benefit in the areas affected by inflammation while avoiding systemic effects. Disturbance in bone acquisition in childhood can reduce peak bone mass and therefore significantly impact the life time risk of osteoporosis.

“One of the challenges has been distinguishing the effects of the inflammatory process itself on bone mass and growth, and the effects of corticosteroids on bone growth from the effects of corticosteroids on bone mass,” she said.

“Analysis of large population databases has recently yielded extremely valuable data about corticosteroids and fractures, with some unexpected impact of lower doses. Analysis of the same database for inhaled steroid use in adults showed a small increase in fracture risk in users of inhaled steroids compared to control, but comparable risk of fracture in inhaled steroid users compared to individuals using inhaled bronchodilators. This suggests that the increased risk of fracture was secondary to the disease itself, not the inhaled steroids,” Dr. Green explained.

Dr. Norman Edelman, chief medical officer of the American Lung Association, noted the benefit of using steroids to treat COPD is still not clear.

“The issue is of importance as combinations of inhaled steroids and long-acting beta agonists are being increasingly marketed and used for COPD,” Edelman said. “Advair is the main one now, Symbicort is likely to be approved for COPD by the FDA soon, and I am told another is on the way.”

The most reasonable conclusion is that inhaled steroids do indeed increase pneumonia in COPD without increasing death from pneumonia, Edelman said.

“On the other hand, the combinations have been shown to decrease exacerbations of COPD and improve function,” he said. “In addition, some data actually suggest, but do not prove, that they prolong life.”

This study suggests that the beneficial effects of the combinations are due to the long-acting beta agonists — bronchodilators — and not the steroids and implies that the way to treat COPD is with these agents alone, Edelman said. “I am sure that we will see more analyses to this point,” he added.

COPD is a major health problem worldwide, but researchers have yet to make the kind of progress made in other major causes of death, Edelman said.

The Edinburgh scientists have spent years devising ways of inducing apoptosis in specific inflammatory cells while, in parallel, driving macrophages to clear the resultant apoptotic cells more rapidly. Now they have shown that CDK inhibitors, like Roscovitine — which is already being tested in human cancer – are capable of inducing neutrophil apoptosis ‘in the test-tube’. Significantly, laboratory tests now suggest that they also reduce inflammation in models of rheumatoid arthritis and a devastating, currently untreatable, lung disease called fibrosing alveolitis.

Professor Chris Haslett, Head of the Queen’s Medical Research Institute at the University of Edinburgh, expects the study to lead to trials of these drugs in human inflammatory diseases. Professors Adriano Rossi and Haslett, who have led this new study with other colleagues from the QMRI, said: “This study offers new hope for patients with severe inflammatory diseases. Specific treatment for such conditions is poor, and the use of steroids is fraught with potential difficulties. We have adopted a different strategy by using non-biological treatments, but this study needs urgently to be translated into trials and we are now seeking major funding to research further how these drugs work.”

Anabolic steroids are synthetic substances similar to the male sex hormone testosterone that promote growth of skeletal muscle and the development of male sexual characteristics.

Although most recently in the news for their misuse by professional athletes, anabolic steroids have legitimate medical application for men with low testosterone and people with certain types of anemia. Two anabolic steroids available in the United States, nandrolone decanoate and oxandrolone, have been used to help increase weight and muscle mass in small studies of people with wasting.

Conversely, anabolic steroid use has been associated with increased rates of HIV in those who share needles or use nonsterile needles when they inject steroids.

In the review studies, anabolic steroids were administered to patients either orally or by injection. The main side effects were mild and included abnormal liver function tests; acne; mild increase in body hair; breast tenderness; increased libido, aggressiveness and irritability; and mood swings — all common side effect of anabolic steroid use.